Protein S

Drug Profile

Protein S

Latest Information Update: 11 Feb 2008

Price : $50

At a glance

  • Originator Hyland Immuno
  • Class Anticoagulants
  • Mechanism of Action Protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 22 Sep 1998 No-Development-Reported for Thrombosis in Austria (Injection)
  • 25 Oct 1995 Preclinical development for Thrombosis in Austria (Injection)
  • 16 Aug 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top